First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER plus breast cancer with KAT6A dysregulation.
癌症
乳腺癌
癌症研究
化学
医学
内科学
作者
Shikhar Sharma,Jay H. Chung,Sean Uryu,Amanda J. Rickard,Natalie Nady,Showkhin Khan,Zhenxiong Wang,Yong Zhang,Haikuo Zhang,Pei‐Pei Kung,Eric Greenwald,Karen A. Maegley,Patrick Bingham,Hieu Lam,Ylva E. Bozikis,Hendrik Falk,Elizabeth Allan,Vicky M. Avery,Miriam Butler,Michelle A. Camerino
出处
期刊:Cancer Research [American Association for Cancer Research] 日期:2021-01-01卷期号:81 (13)被引量:1